GlassScriptPhysician profile
Enrique Valdivia
NPI 1679504054
$18,731.12
in general payments reported to CMS, 2019-2025
44 companies · $5,480 in 2025
The $5,480 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $444 · 2021: $159 · 2022: $2,117 · 2023: $3,829 · 2024: $5,150 · 2025: $5,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,283.91 |
| Education | $175.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,593.05 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Madrigal Pharmaceuticals | $1,825.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $1,494.23 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,431.03 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $1,184.91 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $970.49 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $840.64 | 2022-2025 | |
| Pfizer INC. | $802.05 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $674.68 | 2023-2025 | Iqirvo, Bylvay |
| Qol Medical, LLC | $668.95 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $510.42 | 2022-2025 | Dupixent |
| Celgene Corporation | $491.92 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $416.98 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $399.51 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $273.96 | 2022-2023 | Zeposia |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $256.58 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $204.50 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $183.74 | 2023 | Amvuttra, Givlaari |
| Celltrion USA INC. | $163.17 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Merck Sharp & Dohme LLC | $137.46 | 2022-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $137.15 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $133.40 | 2022-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $121.83 | 2025 | Terlivaz |
| Novo Nordisk INC | $103.84 | 2025 | |
| Aimmune Therapeutics, INC. | $82.47 | 2024-2025 | Vowst |
| Fresenius Kabi USA, LLC | $74.23 | 2023 | Idacio |
| Organon LLC | $63.04 | 2024 | |
| Ferring Pharmaceuticals INC. | $59.53 | 2022-2023 | Rebyota |
| Lucid Diagnostics INC. | $52.72 | 2024 | |
| Abbott Laboratories | $48.05 | 2021 | |
| Shionogi INC | $39.94 | 2019 | |
| Olympus America INC. | $39.75 | 2023-2024 | Endoclot Phs, Visiglide |
| Daiichi Sankyo INC. | $36.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.35 | 2023-2024 | Cyltezo |
| Redhill Biopharma INC. | $28.49 | 2020-2022 | |
| Orphalan INC | $27.33 | 2025 | Cuvrior |
| Biocon Biologics INC | $21.32 | 2025 | Yesintek |
| Evoke Pharma, INC. | $20.74 | 2024 | |
| Acadia Pharmaceuticals INC | $17.94 | 2025 | Daybue |
| Medtronic USA, INC. | $15.57 | 2019 | |
| Medtronic, INC. | $13.77 | 2021 | |
| Braintree Laboratories, INC. | $13.39 | 2022 | |
| Allergan, INC. | $12.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Valdivia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.